BioWorld

June 13, 2003

View Archived Issues

Mouse Leukemic Virus, HIV Rank First, Second In Gene Therapy Sweepstakes - But Oops Factor!

Onyx Cuts Staff Further, Shifts Entire Focus To Bayer Program

InterMune Falls On Lowered Guidance; Reports Positive Data

Durect Seeking $50M Through Offering Of Convertible Notes

Northfield Gets Positive News On Blood Product; Hemosol Set Back

Other News To Note

Pozen Licenses Migraine Drug To GSK In Potential $160M Deal

Pozen Inc. could garner up to at least $160 million after entering a deal with GlaxoSmithKline plc surrounding a migraine treatment. (BioWorld Today) Read More

Maxim Gets Back On Track After Reporting Positive Ceplene Data

Today's news in brief

BioWorld

BioWorld briefs for Jan 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 12, 2026.

3D rendering of antibody drug conjugated with cytotoxic payload

ADCs’ breakout 2025 and their still-unfinished potential

BioWorld

Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...

Science in 2025: the best of the rest

BioWorld Science

A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.

LINC01116 has prognostic value in lung cancer, study shows

BioWorld MedTech

Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate gene expression, translation or...